newsfilter
← Latest News
GlobeNewswire·

Galecto Reports Full-Year 2024 Financial Results

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge